Stereotaxis Receives St. Louis Mayor’s Innovation Award for 2022
Stereotaxis (NYSE: STXS) has been awarded the 2022 Innovation Award by the Office of the Mayor of St. Louis, reflecting its leadership in advancing robotic technologies for minimally invasive heart procedures. The company’s Robotic Magnetic Navigation technology benefits patients with various arrhythmias, having treated over 100,000 globally. Stereotaxis invests over $10 million annually in R&D to enhance healthcare access. Recently, it opened a new 45,000-square-foot headquarters in St. Louis, furthering its commitment to innovation in robotic surgery.
- Awarded the 2022 Innovation Award by the Mayor of St. Louis.
- Robotic Magnetic Navigation technology has treated over 100,000 patients globally.
- Annual investment of over $10 million in research and development.
- Opened a new 45,000-square-foot global headquarters in St. Louis.
- None.
ST. LOUIS, Oct. 03, 2022 (GLOBE NEWSWIRE) -- Stereotaxis (NYSE: STXS), a pioneer and global leader in surgical robotics for minimally invasive endovascular intervention, today announced it was awarded the 2022 Innovation Award from the Office of the Mayor of St. Louis, Tishaura O. Jones. This recognition reflects Stereotaxis’ regional leadership in advancing cutting-edge technologies with a positive impact on society.
Stereotaxis’ Robotic Magnetic Navigation technology is most known for introducing the benefits of robotic precision and safety to minimally invasive procedures performed to treat heart arrhythmias. Tens of millions of individuals worldwide suffer from arrhythmias - abnormal heart rhythms that result when the heart beats too quickly, too slowly, or with an irregular pattern. Hundreds of physicians have used Stereotaxis’ robotic systems to treat over 100,000 patients globally. Multiple clinical publications have demonstrated that the technology supports improved procedural safety and enables physicians to successfully treat the most challenging arrhythmias in patients with otherwise few alternatives.
In recent years, Stereotaxis significantly increased its investment in innovation, and the company spends over
Earlier this year, Stereotaxis opened its 45,000-square-foot global headquarters facility in downtown St. Louis. Located in the renovated historic Globe Building in St. Louis’s growing Downtown North Urban Insight District, the new global corporate headquarters is an all-in-one facility offering high-tech research and development, advanced manufacturing, and distribution space for the company’s pipeline of cutting-edge robotic surgery technologies.
“Stereotaxis has made significant progress in our mission to make the precision and safety of robotics broadly accessible and impactful to patients,” said David Fischel, Chairman and CEO of Stereotaxis. “We are honored to receive this award. It is a reflection of the ingenuity and efforts of many talented individuals on our team in St. Louis and across the globe, as well as the broader community of physicians and partners who are pioneering the advancement of our technology.”
About Stereotaxis
Stereotaxis is the global leader in innovative robotic technologies designed to enhance the treatment of arrhythmias and perform endovascular procedures. Its mission is the discovery, development and delivery of robotic systems, instruments, and information solutions for the interventional laboratory. These innovations help physicians provide unsurpassed patient care with robotic precision and safety, expand access to minimally invasive therapy, and enhance the productivity, connectivity, and intelligence in the operating room. Stereotaxis technology has been used to treat over 100,000 patients across the United States, Europe, Asia, and elsewhere. For more information, please visit www.stereotaxis.com.
This press release includes statements that may constitute "forward-looking" statements, usually containing the words "believe”, "estimate”, "project”, "expect" or similar expressions. Forward-looking statements inherently involve risks and uncertainties that could cause actual results to differ materially. Factors that would cause or contribute to such differences include, but are not limited to, the Company's ability to manage expenses at sustainable levels, acceptance of the Company's products in the marketplace, the effect of global economic conditions on the ability and willingness of customers to purchase its technology, competitive factors, changes resulting from healthcare policy, dependence upon third-party vendors, timing of regulatory approvals, the impact of pandemics or other disasters, and other risks discussed in the Company's periodic and other filings with the Securities and Exchange Commission. By making these forward-looking statements, the Company undertakes no obligation to update these statements for revisions or changes after the date of this release. There can be no assurance that the Company will recognize revenue related to its purchase orders and other commitments because some of these purchase orders and other commitments are subject to contingencies that are outside of the Company's control and may be revised, modified, delayed, or canceled.
| Investor Contacts: David L. Fischel Chairman and Chief Executive Officer Kimberly Peery Chief Financial Officer 314-678-6100 Investors@Stereotaxis.com | Media Contact: Bethanne Schluter Director, Marketing & Communications 314-678-6213 B.Schluter@Stereotaxis.com | |
FAQ
What recognition did Stereotaxis receive in 2022?
How many patients have been treated using Stereotaxis technology?
What is the annual investment by Stereotaxis in research and development?
Where is Stereotaxis' new headquarters located?
